RCT | Trientine tetrahydrochloride noninferior to penicillamine for maintenance therapy in Wilson disease.

Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentary on Twitter

New research – Schilsky et al – Trientine tetrahydrochloride versus penicillamine for maintenance therapy in Wilson disease (CHELATE): a randomised, open-label, non-inferiority, phase 3 trial https://t.co/OS0kh2EkM0#livertwitter #wilsonsdisease #wilsondisease pic.twitter.com/Grizm2uN7F

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) September 30, 2022